Comparison of ophthalmic surgery rates in teprotumumab-treated vs. teprotumumab-untreated thyroid eye disease patients

Taylor J. Linaburg¹; Tejus Pradeep¹; Brian Rinelli¹; Yuanyuan Chen¹; Yineng Chen²; Gui-Shuang Ying²; César A. Briceño¹; Madhura Tamhankar¹

DOI: 10.5935/0004-2749.2024-0319

1. Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA, United States of America
2. Department of Ophthalmology, Center for Preventive Ophthalmology and Biostatistics, University of Pennsylvania, Philadelphia, PA, United States of America

Corresponding author

Taylor J. Linaburg, MD
E-mail: Taylor. Linaburg@pennmedicine.upenn.edu

PDF English Print

How to cite this article:

Linaburg TJ, Pradeep T, Rinelli B, Chen Y, Chen Y, Ying G, et al. Comparison of ophthalmic surgery rates in teprotumumab-treated vs. teprotumumab-untreated thyroid eye disease patients. Arq. Bras. Oftalmol. 2025;88(5):. 10.5935/0004-2749.2024-0319

Export citation